Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

474
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

47
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
47
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

41
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
41

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategies and Timing of Complete Revascularization in STEMI Patients with Multivessel Coronary Artery Disease.

Journal of clinical medicine·2026
Same author

Sex-Dependent Platelet Inhibition with Prasugrel and Ticagrelor after Percutaneous Coronary Intervention in Acute Coronary Syndromes.

Thrombosis and haemostasis·2026
Same author

Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Clinical Impact of Myocardium at Risk in Transcatheter Aortic Valve Implantation.

Circulation. Cardiovascular interventions·2026
Same author

Duration of dual antiplatelet therapy and risk of stent thrombosis in patients undergoing complex PCI: a meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Electrosurgical laceration and stabilisation of tricuspid edge-to-edge repair: the ELASTA-T technique.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Related Experiment Video

Updated: Aug 1, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Renal denervation and long-term results.

Fiorenzo Simonetti1, Raffaele Piccolo1, Giovanni Esposito1

  • 1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|April 24, 2023
PubMed
Summary

Renal denervation offers a valuable option for controlling high blood pressure (hypertension) when medications fail. Recent studies confirm its safety and effectiveness, making it a viable treatment for resistant hypertension.

Keywords:
HypertensionRadiofrequencyRenal denervationResistant hypertensionUltrasound

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

196
A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction
05:51

A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction

Published on: July 18, 2025

52

Related Experiment Videos

Last Updated: Aug 1, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

196
A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction
05:51

A Mouse Model to Evaluate the Long-Term Structural and Functional Outcomes after the Reversal of Prolonged Unilateral Ureteric Obstruction

Published on: July 18, 2025

52

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Nephrology

Background:

  • Arterial hypertension is a prevalent global health issue and a significant risk factor for cardiovascular events.
  • Standard treatments include non-pharmacological methods, pharmacological interventions, and combination therapy to achieve blood pressure (BP) goals.
  • A notable proportion of patients exhibit resistance to drug therapy or experience intolerance to antihypertensive medications.

Purpose of the Study:

  • To evaluate the role of invasive treatments, specifically renal denervation, as a therapeutic option for blood pressure control in patients with resistant hypertension.
  • To reassess the efficacy and safety of renal denervation in light of recent clinical trial data and long-term follow-up.

Main Methods:

  • Review of recent clinical trials and long-term follow-up data on renal denervation procedures.
  • Analysis of the safety and efficacy of renal denervation in achieving blood pressure targets.
  • Consideration of different ablation methods beyond radiofrequency.

Main Results:

  • Recent data from new trials and long-term follow-up have re-established the benefit and safety of renal denervation.
  • The procedure is being relaunched into clinical practice for managing resistant hypertension.
  • Initial concerns regarding negative trial results have been addressed by subsequent evidence.

Conclusions:

  • Renal denervation is a valuable therapeutic option for patients with hypertension unresponsive to conventional treatments.
  • Further research into various ablation techniques is necessary to optimize patient selection and procedural outcomes.
  • The procedure's role in managing resistant hypertension is being redefined and expanded.